TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study
Brief Summary: Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).

Primary Objective of the study:

To evaluate the long-term safety and tolerability of alirocumab in high cardiovascular risk participants with hypercholesterolemia not adequately controlled with their current lipid modifying therapy (LMT).

Secondary Objectives:

* To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.
* To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points.
* To evaluate the effects of alirocumab on other lipid parameters.


Options:
A: Arm Label: Alirocumab therapy group; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab | Arm Label: standard statin therapy group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab therapy group
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo
C: Arm Label: ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe/simvastatin, Drug: Placebo for simvastatin 40 mg | Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: Placebo for simvastatin 40 mg, Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo for simvastatin 40 mg; Assigned to Arm(s): ezetimibe/simvastatin, simvastatin | Intervention Type: DRUG; Name: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination; Assigned to Arm(s): simvastatin
D: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Other: Standard of care | Arm Label: Evolocumab + SOC; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + SOC, Standard of Care | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Misoprostol for the Treatment of Postpartum Haemorrhage (PPH) Following Self- Administration of Misoprostol Prophylaxis in Home Deliveries.
Brief Summary: Misoprostol, a prostaglandin E1 that induces uterine contractions, has been proposed as a low cost, easy-to-use option for prevention and treatment of Postpartum Haemorrhage (PPH), especially in settings where injectable uterotonics are not yet available or feasible to use.

A double-blinded individual randomized controlled study of misoprostol versus placebo in home deliveries in four districts in the Badakshan Province in Afghanistan. The study will recruit pregnant women who are likely to deliver at home. All women enrolled in the study will receive 600 mcg misoprostol to be self-administered as prophylaxis for PPH after delivery of their baby (ies) and before delivery of the placenta.

Women who experience a PPH will be randomized to receive either: a) standard of care + 800 mcg misoprostol (four 200 mcg tablets) or b) standard of care + four placebo tablets resembling misoprostol. In this setting, standard of care is referral.


Options:
A: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol
C: Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MISOPROSTOL; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): MISOPROSTOL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age
Brief Summary: The primary objective of this study is to characterize the safety, and efficacy of Dexmedetomidine (DEX) administered as an intravenous (IV) loading dose followed by a continuous IV infusion in preterm subjects, ages ≥ 28 weeks through \< 36 weeks gestational age.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): 2
C: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine, Drug: Midazolam, Drug: Fentanyl, Drug: Morphine | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexmedetomidine
D: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN)
Brief Summary: The Membranous Nephropathy is one of the most common cause of Nephrotic Syndrome of adults. In 2/3 of patients the cause of the disease is idiopathic. This can also be referred to as idiopathic membranous nephropathy (IMN).The most of these patients are treated by non immunosuppressive symptomatic treatment (NIST): antiproteinuric and antihypertensive blocking the rennin-angiotensine system. However, the patients resistant to antiproteinuric treatment risk to develop an end stage renal disease (ESRD).

Rituximab has been recently used in patients suffering of nephrotic syndrome related to IMN in four international studies. Rituximab appears effective and safe in reducing proteinuria in nearly 60% of patients.

The primary outcome of the investigators prospective randomized study is to determine whether or not the Rituximab associated with NIST is more effective than non immunologic symptomatic treatment alone in inducing long term remission of proteinuria.


Options:
A: Arm Label: active comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin) | Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | Intervention Type: DRUG; Name: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin); Assigned to Arm(s): active comparator | Intervention Type: DRUG; Name: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab); Assigned to Arm(s): experimental
B: Arm Label: RITUXIMAB; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Corticosteroids and Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): RITUXIMAB | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Corticosteroids and Cyclophosphamide | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Corticosteroids and Cyclophosphamide
C: Arm Label: prednisone; Type: N/A; Interventions: N/A | Arm Label: prednisone and anti-virus; Type: N/A; Interventions: N/A
D: Arm Label: Mycophenolate mofetil, low dose steroid; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil, low dose steroid | Arm Label: Cyclosporin, low dose steroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporin, low dose steroid | Intervention Type: DRUG; Name: Mycophenolate mofetil, low dose steroid; Assigned to Arm(s): Mycophenolate mofetil, low dose steroid | Intervention Type: DRUG; Name: Cyclosporin, low dose steroid; Assigned to Arm(s): Cyclosporin, low dose steroid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rehabilitation and Exercise Training After Hospitalization: Assessing Benefit in Acute Heart Failure (REHAB-HF) Pilot Study
Brief Summary: Rehabilitation and Exercise Training after Hospitalization: Assessing Benefit in Acute Heart Failure (REHAB-HF) pilot is a multi-site, randomized clinical pilot study designed to establish the feasibility of conducting a larger clinical trial to address the hypothesis that, in addition to standard care, a novel, progressive, multi-domain 3-month rehabilitation intervention administered to elderly patients with acute decompensated heart failure (ADHF) will improve key clinical outcomes, including the rate of rehospitalization and death, physical function, and quality of life.


Options:
A: Arm Label: Walking intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walking intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking intervention; Assigned to Arm(s): Walking intervention
B: Arm Label: No intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): No intervention | Intervention Type: BEHAVIORAL; Name: Rehabilitation intervention; Assigned to Arm(s): Active Comparator
C: Intervention Type: BEHAVIORAL; Name: Aerobic endurance exercise training (ergometer); Assigned to Arm(s): N/A
D: Arm Label: Walking intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walking intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking intervention; Assigned to Arm(s): Walking intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Controlled Trial of Early Post-operative Removal of Urethral Catheter in Patients Undergoing Colorectal Surgery With Epidural Analgesia
Brief Summary: Patients undergoing colon or rectal surgery will usually have a urinary catheter (silicone tube) placed in the bladder at the time of operating to monitor kidney function during surgery and in the post-surgery period. Such patients will also have an infusion into the spine, known as an epidural, after surgery to provide them with continuous pain relief. Urinary catheters should be removed as early as possible once they are no longer required to facilitate patients becoming mobile after surgery and to reduce the risk of patients developing a urinary tract infection.

Traditionally these catheters are not removed until the patients epidural infusion is withdrawn, as in theory to do so would predispose the patient to developing acute retention of urine due to lack of sensation when the bladder is full. The investigators hypothesis is that urinary catheters placed via the urethra can be withdrawn 48 hours after colon/rectal surgery in patients receiving epidural pain relief without a significant increase in rates of urinary retention.


Options:
A: Arm Label: Study group 1; Type: EXPERIMENTAL; Interventions: Other: Removal of urethral catheter | Arm Label: Study group 2; Type: OTHER; Interventions: Other: Removal of urethral catheter | Intervention Type: OTHER; Name: Removal of urethral catheter; Assigned to Arm(s): Study group 1, Study group 2
B: Arm Label: Drotaverine; Type: N/A; Interventions: N/A | Arm Label: Control; Type: N/A; Interventions: N/A
C: Arm Label: Autofill Void Trial; Type: ACTIVE_COMPARATOR; Interventions: Device: Void Trial using Foley catheter | Arm Label: Backfill Void Trial; Type: ACTIVE_COMPARATOR; Interventions: Device: Void Trial using Foley catheter | Intervention Type: DEVICE; Name: Void Trial using Foley catheter; Assigned to Arm(s): Autofill Void Trial, Backfill Void Trial
D: Arm Label: removal of catheter; Type: OTHER; Interventions: Procedure: immediate removal of in-dwelling catheter, Procedure: 24 hours delayed removal of catheter | Intervention Type: PROCEDURE; Name: immediate removal of in-dwelling catheter; Assigned to Arm(s): removal of catheter | Intervention Type: PROCEDURE; Name: 24 hours delayed removal of catheter; Assigned to Arm(s): removal of catheter

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia
Brief Summary: The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia.


Options:
A: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Biological: Auto-CD34+ cells | Arm Label: Active Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: Diluent used to suspend Auto-CD34+ cells | Arm Label: Unblinded Standard of Care (SOC) Arm; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: BIOLOGICAL; Name: Auto-CD34+ cells; Assigned to Arm(s): Treatment Arm | Intervention Type: BIOLOGICAL; Name: Placebo: Diluent used to suspend Auto-CD34+ cells; Assigned to Arm(s): Active Control Arm | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Unblinded Standard of Care (SOC) Arm
B: Arm Label: Placebo Injections; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Active Stem Cell Injections; Type: EXPERIMENTAL; Interventions: Biological: Adult stem cells | Intervention Type: BIOLOGICAL; Name: Adult stem cells; Assigned to Arm(s): Active Stem Cell Injections | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Injections
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ranolazine placebo | Arm Label: Ranolazine; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Ranolazine placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Ranolazine | Intervention Type: DRUG; Name: Ranolazine placebo; Assigned to Arm(s): Placebo, Ranolazine
D: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma
Brief Summary: The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to baseline blood eosinophil levels in patients with moderate to severe asthma, as assessed by the change from baseline to week 16 in forced expiratory volume in 1 second (FEV1).


Options:
A: Arm Label: 1; Type: N/A; Interventions: N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A, B, C
D: Arm Label: Placebo (for Dupilumab); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone/Salmeterol combination therapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone monotherapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Levalbuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma
Brief Summary: The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to baseline blood eosinophil levels in patients with moderate to severe asthma, as assessed by the change from baseline to week 16 in forced expiratory volume in 1 second (FEV1).


Options:
A: Arm Label: Placebo (for Dupilumab); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone/Salmeterol combination therapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone monotherapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Levalbuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo
D: Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): N/A

Answer: B